Blog

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the presentation of results from its lead programs at the 6th International Neurology & Brain Disorders Conference (INBC) to be held on October 24-26, 2022, in Orlando, Florida (https://neurologycongress.com). The Company’s poster presentations will demonstrate the comprehensive innovation processes behind the rapid development of a large library of new chemical entity (NCE) drug candidates encompassing significant structural diversity and exhibiting therapeutically relevant neuroactive properties. Enveric’s first poster presentation, related to the EVM201 development program, describes the…

Reunion Neuroscience Inc. (TSX: REUN | NASDAQ: REUN), a leader in novel serotonergic psychedelic drug development committed to innovating proprietary therapeutic solutions for mental health conditions, announced today that the Company’s President and CEO, Mr. Greg Mayes, will participate on a panel at this year’s Horizons Perspectives on Psychedelics conference, taking place at the New York Academy of Medicine in New York City. The panel session, titled, “Raising Capital for Psychedelic Endeavors,” is part of the conference’s Psychedelic Business Forum and will focus on how both companies and funds are raising capital to expand their business interests in the growing field of psychedelic medicine. The panel will…

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it will host a virtual update for investors and shareholders on Wednesday, October 19, 2022 at 2:00 p.m. Eastern (11:00 a.m. Pacific). During the event, Chief Executive Officer (CEO) Benjamin Lightburn and Chief Science Officer (CSO) Ryan Moss will discuss Filament’s recent progress including intellectual property developments, a successful financing, an FDA-approved clinical trial in partnership with the University of California San Francisco, and plans for future growth. The discussion will be followed by a question-and-answer session with the Company’s senior management team. WHO:              Benjamin Lightburn, CEO,…

PharmAla Biotech (CSE: MDMA) is pleased to announce that it has retained Clerkenwell Health, a UK-based Contract Research Organization, to assist PharmAla in regulatory proceedings with both the US Food and Drug Administration (FDA) and the UK Medicines and Health Regulatory Authority (MHRA). PharmAla intends to bring ALA-002, its leading Novel Chemical Entity (NCE), to both jurisdictions. ALA-002 was designed to provide the same efficacy as MDMA, has an improved safety profile, including Cardio- and Neuro-tox, and fewer adverse events. “PharmAla have a unique and exciting strategy, which could present real improvements to clinical development and application of empathogens. Engaging with both the MHRA and the FDA…

That title has an ironic ring to it, doesn’t it? Psychedelics once sparked one of the biggest movements of peace that this world has ever known. They inspired compassion and oneness in millions of people. Today, the race to profit off of patents and intellectual property has turned psychedelic headlines into the pharmaceutical feuds that psychedelic biotech and its leaders were meant to overcome. Controversy over patents for psychedelic compounds has been at the forefront of discussions this year. Biotech companies are racing to bring drugs to market that will change the face of depression, anxiety, PTSD, and addiction treatment….